CN103479630B - The application of Lycojaponicumin A in preparation treatment breast cancer medicines - Google Patents
The application of Lycojaponicumin A in preparation treatment breast cancer medicines Download PDFInfo
- Publication number
- CN103479630B CN103479630B CN201310441982.3A CN201310441982A CN103479630B CN 103479630 B CN103479630 B CN 103479630B CN 201310441982 A CN201310441982 A CN 201310441982A CN 103479630 B CN103479630 B CN 103479630B
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- lycojaponicumin
- application
- preparation treatment
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 25
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- WGVQKABRYXBLGW-WUZBVLBZSA-N (1R,2S,5S,7S,10S,13S)-7-hydroxy-7-methyl-17-oxa-14-azapentacyclo[12.2.1.02,10.02,13.05,10]heptadecane-3,9-dione Chemical compound O=C([C@@]12CC3)C[C@@](C)(O)C[C@H]1CC(=O)[C@@]12[C@H]3N2CC[C@H]1O2 WGVQKABRYXBLGW-WUZBVLBZSA-N 0.000 title claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000012010 growth Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 229930185194 lycojaponicumin Natural products 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Do you the invention discloses Lycojaponicumin? the application of A in preparation treatment breast cancer medicines, belongs to technical field of new application of medicine.Is the present invention found by external MTT antineoplastic activity evaluation, Lycojaponicumin? A also has significant inhibitory action to the growth of Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B.Therefore, Lycojaponicumin? A for the preparation of anti-breast cancer medicines, can have good development prospect.For the Lycojaponicumin that the present invention relates to? the purposes of A in preparation treatment breast cancer medicines belongs to first public, and because framework types belongs to brand-new framework types, and its inhibit activities for breast cancer cell is unexpectedly strong.
Description
Technical field
The present invention relates to the novelty teabag of compound L ycojaponicuminA, particularly relate to LycojaponicuminA and preparing the application in anti-breast cancer medicines.
Technical background
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound L ycojaponicuminA that the present invention relates to is one and delivers (Wang in 2012, X.J.etal., 2012.LycojaponicuminsA-C, ThreeAlkaloidswithanUnprecedentedSkeletonfromLycopodiumj aponicum.OrganicLetters14 (10), New skeleton compound 2614-2617.), this compound has brand-new framework types, the purposes of the LycojaponicuminA that the present invention relates in preparation treatment breast cancer medicines is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for breast cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for breast carcinoma obviously has significant progress.
Summary of the invention
The invention provides compound L ycojaponicuminA and prepare the application in antitumor drug.
The present invention adopts following technical scheme: LycojaponicuminA is preparing the application in anti-breast cancer medicines, and the structural formula of LycojaponicuminA is as shown in formula I:
The present invention is found by external MTT antineoplastic activity evaluation, and LycojaponicuminA also has significant inhibitory action to the growth of Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 2.19 ± 0.23 μMs, 1.35 ± 0.15 μMs, 2.21 ± 0.27 μMs and 1.12 ± 0.17 μMs.Therefore, LycojaponicuminA for the preparation of anti-breast cancer medicines, can have good development prospect.
The purposes of the LycojaponicuminA that the present invention relates in preparation treatment breast cancer medicines belongs to first public, because framework types belongs to brand-new framework types, and its inhibit activities for breast cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for breast carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound L ycojaponicuminA involved in the present invention is see document (Wang, X.J.etal., 2012.LycojaponicuminsA-C, ThreeAlkaloidswithanUnprecedentedSkeletonfromLycopodiumj aponicum.OrganicLetters14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicuminA tablet involved in the present invention:
Get 20 g of compound LycojaponicuminA, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound L ycojaponicuminA capsule involved in the present invention:
Get 20 g of compound LycojaponicuminA, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound LycojaponicuminA to the growth inhibited effect of Breast cancer lines
1. method: the cell being in growth logarithmic (log) phase: Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B (buying from Chinese Academy of Sciences's cell bank) are with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the LycojaponicuminA of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ LDMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. the growth of result: LycojaponicuminA to Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B has significant inhibitory action.This compound suppresses the IC of Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B growth
50value is respectively: 2.19 ± 0.23 μMs, 1.35 ± 0.15 μMs, 2.21 ± 0.27 μMs and 1.12 ± 0.17 μMs.
Shown by above-described embodiment, the growth of LycojaponicuminA of the present invention to Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B has good inhibitory action.Prove thus, LycojaponicuminA of the present invention has anti-breast cancer activity, can for the preparation of anti-breast cancer medicines.
Claims (1)
1.LycojaponicuminA preparation treatment breast cancer medicines in application, described compound L ycojaponicuminA structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310441982.3A CN103479630B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin A in preparation treatment breast cancer medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310441982.3A CN103479630B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin A in preparation treatment breast cancer medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479630A CN103479630A (en) | 2014-01-01 |
| CN103479630B true CN103479630B (en) | 2015-12-02 |
Family
ID=49820453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310441982.3A Active CN103479630B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin A in preparation treatment breast cancer medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479630B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
-
2013
- 2013-09-23 CN CN201310441982.3A patent/CN103479630B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Lycojaponicumins AC, Three Alkaloids;xiao-jing wang,etc;《organic letters》;20121231;第14卷(第10期);2614-2617 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479630A (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463046B (en) | The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine | |
| CN102872086B (en) | The application of Houttuynoid A in treatment skin carcinoma medicine | |
| CN103479630B (en) | The application of Lycojaponicumin A in preparation treatment breast cancer medicines | |
| CN103462969B (en) | The application of Incarviatone A in preparation treatment breast cancer medicines | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103446128B (en) | The application of Lycojaponicumin B in preparation treatment skin carcinoma medicine | |
| CN103479633B (en) | The application of Lycojaponicumin B in preparation treatment medicine for nasopharyngeal | |
| CN103463072B (en) | The application of Lycojaponicumin C in preparation treatment bladder cancer medicine | |
| CN103463054B (en) | The application of Lycojaponicumin A in preparation treatment bladder cancer medicine | |
| CN103446146B (en) | The application of Lycojaponicumin C in preparation treatment blindgut cancer | |
| CN103463049B (en) | The application of Lycojaponicumin B in preparation treatment breast cancer medicines | |
| CN103446133B (en) | The application of Lycojaponicumin B in preparation treatment tongue cancer drug | |
| CN103463044B (en) | The application of Lycojaponicumin A in preparation treatment skin carcinoma medicine | |
| CN103463034B (en) | The application of Lycojaponicumin B in preparation treatment ovarian cancer | |
| CN103494812B (en) | The application of Lycojaponicumin A in preparation treatment ovarian cancer | |
| CN103463024B (en) | The application of Lycojaponicumin B in preparation treatment renal carcinoma medicine | |
| CN103446088B (en) | The application of Incarviatone A in preparation treatment skin carcinoma medicine | |
| CN103479632B (en) | The application of Lycojaponicumin B in preparation treatment cervical cancer medicine | |
| CN103463078B (en) | The application of Lycojaponicumin C in preparation treatment renal carcinoma medicine | |
| CN103463020B (en) | The application of Lycojaponicumin A in preparation treatment renal carcinoma medicine | |
| CN103463052B (en) | The application of Lycojaponicumin A in preparation treatment cervical cancer medicine | |
| CN103463070B (en) | The application of Lycojaponicumin C in preparation treatment breast cancer medicines | |
| CN103446147B (en) | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine | |
| CN103463061B (en) | The application of Lycojaponicumin C in preparation treatment carcinoma of prostate medicine | |
| CN103405444B (en) | The application of Chukrasone A in preparation treatment bladder cancer medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Hongli Inventor before: Jiang Chunping Inventor before: Wang Zezheng |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151104 Address after: 325011, building 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Zhejiang, Wenzhou Applicant after: Wenzhou Chengqiao Technology Co.,Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180823 Address after: 529300 1 Harbour City villa area, Guangming East Road, Changsha, Kaiping, Guangdong. Patentee after: Kuang Wenzhan Address before: 325011 room 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Wenzhou, Zhejiang. Patentee before: Wenzhou Chengqiao Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181108 Address after: 529300 Industrial Development Zone, Sha Tang Town, Kaiping, Guangdong Patentee after: Guangdong Bio Pharmaceutical Co., Ltd. Address before: 529300 1 Harbour City villa area, Guangming East Road, Changsha, Kaiping, Guangdong. Patentee before: Kuang Wenzhan |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder |
Address after: 529300 No. 4-1, Shatang Town, Kaiping, Jiangmen City, Guangdong Province Patentee after: Guangdong Bio Pharmaceutical Co., Ltd. Address before: 529300 Industrial Development Zone, Sha Tang Town, Kaiping, Guangdong Patentee before: Guangdong Bio Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |